According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center , published today in Nature Medicine , the ...
GlobalData on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
A recent study showed six out of ten men and women with grey hair saw the colour come back to at least half of their hair ...
Your dermatologist or oncologist may have told you what type of advanced squamous cell carcinoma you have. Here’s what each type means: Locally advanced squamous cell carcinoma: This means cancer has ...
A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...
HPV status, particularly combined p16 and HPV positivity, is vital for patient selection in de-escalation strategies for ...
Alshehri, E. (2026) The Diagnostic Conundrum of Recurrent High-Grade Vaginal Intraepithelial Neoplasia (VAIN) Following ...
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
Two antibody-drug conjugates are among 10 programs that the company expects to fuel its growth, the company said.
The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback